[1] TSAO C W, ADAY A W, ALMARZOOQ Z I, et al.Heart Disease and Stroke Statistics-2022 Update: A Report From the American Heart Association[J]. Circulation,2022,145(8):e153-e639. [2] WANG Y J, LI Z X, GU H Q, et al.“China Stroke Statistics 2019: A Report From the National Center for Healthcare Quality Management in Neurological Diseases, China National Clinical Research Center for Neurological Diseases, the Chinese Stroke Association, National Center for Chronic and Non-communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention and Institute for Global Neuroscience and Stroke Collaborations.”[J]. Stroke and vascular neurology,2020,5(3):211-239. [3] CHEN H, YOSHIOKA H, KIM G S, et al.Oxidative stress in ischemic brain damage: mechanisms of cell death and potential molecular targets for neuroprotection[J]. Antioxid Redox Signal,2011,14(8):1505-1517. [4] AJOOLABADY A, WANG S, KROEMER G, et al.Targeting autophagy in ischemic stroke: From molecular mechanisms to clinical therapeutics[J].Pharmacology & Therapeutics,2021,225:107848. [5] JIANG X, ANDJELKOVIC A V, ZHU L, et al. Blood-brain barrier dysfunction and recovery after ischemic stroke[J]. Progress in Neurobiology,2018,163-164:144-171. [6] MO Y, SUN Y Y, LIU K Y.Autophagy and inflammation in ischemic stroke[J]. Neural Regeneration Research,2020,15(8):1388-1396. [7] SINGH V, MISHRA V N, CHAURASIA R N, et al.Modes of Calcium Regulation in Ischemic Neuron[J]. Indian J Clin Biochem,2019,34(3):246-253. [8] GARTZIANDIA O, EGUSQUIAGUIRRE S P, BIANCO J, et al.Nanoparticle transport across in vitro olfactory cell monolayers[J]. Int J,Pharm,2016,499(1-2):81-89. [9] 吕莹. 鼻腔给药研究进展[J].天津中医药,2014,31(12):766-768. [10] ERDŐ F, BORS L A, FARKAS D, et al.Evaluation of intranasal delivery route of drug administration for brain targeting[J]. Brain Res Bull, 2018,143:155-170. [11] CHAPMAN C D, FREY W H 2nd, CRAFT S, et al. Intranasal Treatment of Central Nervous System Dysfunction in Humans[J].Pharmaceutical Research,2012,30(10):2475-2484. [12] YANG J P, LIU H J, WANG Z L, et al.The dose-effectiveness of intranasal VEGF in treatment of experimental stroke[J]. Neuroscience Letters,2009,461(3):212-216. [13] 杨开清. 脑醒喷鼻剂治疗急性缺血性中风66例[J].广州中医药大学学报,2003(1):28-30. [14] GU J H, GE J B, LI M, et al.Inhibition of NF-κB activation is associated with anti-inflammatory and anti-apoptotic effects of Ginkgolide B in a mouse model of cerebral ischemia/reperfusion injury[J]. Eur J Pharm Sci,2012,47(4):652-660. [15] NABAVI S M, HABTEMARIAM S, DAGLIA M, et al.Neuroprotective Effects of Ginkgolide B Against Ischemic Stroke: A Review of Current Literature[J]. Curr Top Med Chem,2015,15(21):2222-2232. [16] 唐永鑫. 白果内酯对脑缺血损伤保护作用的研究进展[J].药物评价研究,2018,41(7):1203-1209. [17] FENG Z, SUN Q, CHEN W, et al.The neuroprotective mechanisms of ginkgolides and bilobalide in cerebral ischemic injury: a literature review[J]. Mol Med,2019,25(1):57. [18] LONGA E Z, WEINSTEIN P R, CARLSON S, et al.Reversible middle cerebral artery occlusion without craniectomy in rats[J]. Stroke, 1989,20(1):84-91. [19] 金振东. 银杏内酯注射液对脑缺血再灌注小鼠炎症水平的影响[J].临床医药文献电子杂志,2018,5(76):1-5. [20] 邬春久. 银杏内酯注射液及其组分对大鼠缺血性脑卒中模型作用比较及对突触后致密物95表达的影响[J].药物评价研究,2019,42(6):1110-1114,1145. [21] CARMICHAEL S T.Rodent models of focal stroke: size, mechanism, and purpose[J]. NeuroRx,2005,2(3):396-409. |